Marrying immunotherapy with chemotherapy: why say IDO?
Activation of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) in cancer cells facilitates immune escape. A recent study now shows how small-molecule inhibitors of IDO can be used to leverage the efficacy of traditional chemotherapeutic drugs that are used to treat cancer in the clinic. By promoting antitumor immune responses in combination with cytotoxic chemotherapy, IDO inhibitors may offer a drug-based strategy to more effectively attack systemic cancer.
Muller
Alexander J
AJ
Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA. mullera@mlhs.org
Prendergast
George C
GC
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000037:antagonists & inhibitors* / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000276:immunology* / Q000628:therapy*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase